About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2024-11-20
Cancer Communications Published the Results of HLX07-ESCC201: HLX07 as monotherapy or combination therapy in ESCC
2024-11-19
Henlius to Showcase Latest Results of 5 Clinical Trails at ESMO Asia 2024
2024-11-07
Henlius and SVAX Forge Strategic Partnership in the MENAT Market
2024-11-05
Latest Research into the Differentiated Mechanisms of Action of Serplulimab Published in mAbs Journal
2024-10-30
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
2024-10-24
First Patient in Japan Dosed for MRCT Phase 3 Study on First-Line mCRC of Henlius Anti-PD-1 mAb Serplulimab
2024-10-23
HLX22 Dual HER2 Blockade Therapy Featured on the Cover of Med
2024-10-21
Henlius Receives Approval in Japan for Phase 3 MRCT of Dual HER2 Blockade Therapy on First-Line HER2+ GC
2024-10-14
Henlius Shines at CPHI Worldwide 2024, Expanding New Opportunities for International Collaboration
1
2
3
4
...
39
